---
title: Patient Perspectives in Squamous Cell Carcinoma Clinical Trials
nct_id: NCT05929547
overall_status: NOT_YET_RECRUITING
sponsor: Power Life Sciences Inc.
study_type: OBSERVATIONAL
primary_condition: Squamous Cell Carcinoma
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05929547.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05929547"
ct_last_update_post_date: 2023-07-03
last_seen_at: "2026-05-12T06:43:11.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Patient Perspectives in Squamous Cell Carcinoma Clinical Trials

**Official Title:** An In Depth Study Examining Patterns in the Clinical Trial Experiences of Squamous Cell Carcinoma Patients

**NCT ID:** [NCT05929547](https://clinicaltrials.gov/study/NCT05929547)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 500
- **Lead Sponsor:** Power Life Sciences Inc.
- **Conditions:** Squamous Cell Carcinoma
- **Start Date:** 2024-07
- **Completion Date:** 2026-07
- **CT.gov Last Update:** 2023-07-03

## Brief Summary

Clinical research participation has historically been heavily biased toward specific demographics.

This study will invite several participants to gather a wide range of information on clinical trial experiences for squamous cell carcinoma patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of squamous cell carcinoma.

People with squamous cell carcinoma who are invited to take part in clinical research will benefit from the analysis of the data.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Aged ≥ 18 years old
* Confirmed diagnosis of squamous cell carcinoma
* Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.

Exclusion Criteria:

* Inability to provide written informed consent
* Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study
* Enrolled in another research study
```

## Primary Outcomes

- **Number of patients who decide to enroll in a squamous cell carcinoma clinical trial** _(time frame: 3 months)_
- **Rate of patients who remain in squamous cell carcinoma clinical trial to trial completion** _(time frame: 12 months)_

## Locations (1)

- Power Life Sciences, San Francisco, California, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.power life sciences|san francisco|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05929547.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05929547*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*